[1]赵 锐.拉米夫定联合替诺福韦与依非韦伦治疗艾滋病的临床效果及对肝功能的影响[J].医学信息,2023,36(15):124-127.[doi:10.3969/j.issn.1006-1959.2023.15.025]
　ZHAO Rui.Clinical Effect of Lamivudine Combined with Tenofovirdisoproxil and Efavirenz in the Treatment of AIDS and its Effect on Liver Function[J].Journal of Medical Information,2023,36(15):124-127.[doi:10.3969/j.issn.1006-1959.2023.15.025]
点击复制

拉米夫定联合替诺福韦与依非韦伦治疗艾滋病的临床效果及对肝功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年15期
页码:
124-127
栏目:
论著
出版日期:
2023-08-01

文章信息/Info

Title:
Clinical Effect of Lamivudine Combined with Tenofovirdisoproxil and Efavirenz in the Treatment of AIDS and its Effect on Liver Function
文章编号:
1006-1959（2023）15-0124-04
作者:
赵 锐
（抚州市临川区疾病预防控制中心艾防科，江西 抚州 344100）
Author(s):
ZHAO Rui
(Department of AIDS Prevention and Control,Linchuan District Center for Disease Control and Prevention,Fuzhou 344100,Jiangxi,China)
关键词:
拉米夫定; 替诺福韦; 依非韦伦; 艾滋病; 肝功能
Keywords:
Lamivudine; Tenofovirdisoproxil; Efavirenz; AIDS; Liver function
分类号:
R512.91
DOI:
10.3969/j.issn.1006-1959.2023.15.025
文献标志码:
A
摘要:
目的 观察拉米夫定联合替诺福韦与依非韦伦治疗艾滋病的临床效果及对肝功能的影响。方法 选取2021年1月-2022年1月在我中心诊治的100例艾滋病患者为研究对象，采用随机数字表法分为对照组（n=50）和观察组（n=50），对照组采用拉米夫定联合依非韦伦治疗，观察组在对照组基础上联合应用替诺福韦，比较两组临床治疗效果、血HIV病毒载量、肝功能指标[谷丙转氨酶（ALT）、谷草转氨酶（AST）及总胆红素（T-Bil）]、免疫功能指标（CD4+、CD8+）以及不良反应发生情况。结果 观察组治疗总有效率为94.00%，高于对照组的80.00%（P＜0.05）；两组治疗后血HIV病毒载量均低于治疗前，且观察组低于对照组（P＜0.05）；两组治疗后ALT、AST、T-Bil均升高，但是观察组低于对照组（P＜0.05）；两组治疗后CD4+ 、CD8+均高于治疗前，且观察组高于对照组（P＜0.05）；观察组不良反应发生率为6.00%，与对照组的8.00%比较，差异无统计学意义（P＞0.05）。结论 拉米夫定联合替诺福韦和依非韦伦治疗艾滋病的临床效果确切，可提高治疗有效率，降低HIV病毒载量，减轻肝功能损伤，促进免疫功能改善，且不会增加不良反应，是一种安全、有效的联合用药治疗方案。
Abstract:
Objective To evaluate the clinical efficacy of lamivudine combined with tenofovirdisoproxil and efavirenz in the treatment of aids and its effect on liver function.Methods A total of 100 AIDS patients diagnosed and treated in our center from January 2021 to January 2022 were selected as the research objects. They were divided into control group (n=50) and observation group (n=50) by random number table method. The control group was treated with lamivudine combined with efavirenz, and the observation group was treated with tenofovirdisoproxil on the basis of the control group. The clinical treatment effect, blood HIV viral load, liver function indexes [alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (T-Bil)], immune function indexes (CD4+, CD8+) and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 94.00%, which was higher than 80.00% in the control group (P<0.05). The blood HIV viral load of the two groups after treatment was lower than that before treatment, and that of the observation group was lower than that of the control group (P<0.05). After treatment, ALT, AST and T-Bil increased in both groups, but those in the observation group were lower than those in the control group (P<0.05). After treatment, CD4+ and CD8+ in the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 6.00%, which was compared with 8.00% in the control group, the difference was not statistically significant (P>0.05).Conclusion Lamivudine combined with tenofovirdisoproxil and efavirenz has a definite clinical effect in the treatment of AIDS, which can improve the treatment efficiency, reduce HIV viral load, reduce liver function damage, promote immune function improvement, and will not increase clinical adverse reactions. It is a safe and effective combination therapy.

参考文献/References:

[1]李繁,谢睿彬,李远,等.替诺福韦/拉米夫定/依非韦伦联合治疗老年HIV/AIDS疗效分析[J].右江民族医学院学报,2016,38(5):493-495.[2]黄敬泉,王传香,钟启盛.拉米夫定、替诺福韦、依非韦伦联合治疗艾滋病效果[J].齐鲁医学杂志,2017,32(4):421-423.[3]周敏.替诺福韦酯联合拉米夫定、依非韦伦对艾滋病合并乙型肝炎病毒感染的治疗效果与安全性分析[J].医学信息,2016,29(32):50-51.[4]杨蓉蓉,桂希恩,熊勇,等.两种非核苷类逆转录酶抑制剂治疗艾滋病的不良反应分析[J].国际流行病学传染病学杂志,2017,44(4):233-236.[5]吴明杰.替诺福韦酯联合拉米夫定、依非韦伦对艾滋病合并乙型肝炎病毒感染的治疗效果与安全性评价[J].中外医学研究,2019,17(2):147-148.[6]中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防与控制中心.中国艾滋病诊疗指南（2018版）[J].传染病信息,2018,31(6):481-499.[7]苏琛,彭鑫,胡增,等.中药联合含依非韦伦的HAART方案对HIV/AIDS病人的中枢神经系统不良反应及疗效分析[J].中国艾滋病性病,2019,25(9):899-901,905.[8]覃川,蒋忠胜,苏明华,等.含替诺福韦的一线HAART方案治疗HIV感染/AIDS患者的疗效及治疗失败的影响因素[J].广西医学,2019,41(11):1341-1345.[9]林永年,何秀华,高艺鹏,等.替诺福韦片联合拉米夫定片和洛匹那韦利托那韦片治疗艾滋病的临床研究[J].中国临床药理学杂志,2018,34(15):88-90.[10]刘欢霞,蔡琳,朱迎春,等.282例HIV/AIDS患者TDF+3TC+EFV初始抗病毒治疗效果分析[J].重庆医学,2019,48(2):104-106,110.[11]Martin RW,Brogard Andersen S,O＇Brien MA,et al.Providing balanced information about options in patient decision aids: an update from the international patient decision aid standards[J].Med Decis Making,2021,41(7):780-800.[12]彭文绣,付强,杜小莉,等.HBV/HCV共感染对依非韦伦在HIV/AIDS患者血药浓度、疗效及肝毒性的影响[J].中国药学杂志,2019,37(14):68-72.[13]谭清,周仲辉,严冬梅,等.成年人类免疫缺陷病毒感染者/艾滋病患者长期抗病毒治疗后免疫功能重建分析[J].中国全科医学,2020,23(23):2918-2922.[14]王莹莹,杨海涛,王永红,等.石家庄市358例艾滋病患者抗逆转录病毒治疗后生存分析及危险因素研究[J].中华疾病控制杂志,2018,24(77):90-94.[15]郭伏平,李太生.中国人类免疫缺陷病毒感染者依非韦伦浓度前瞻性评估研究[J].中华内科杂志,2018,57(11):846-847.[16]Huang W,Li T,Zhou C,et al.Voriconazole versus amphotericin b as induction therapy for talaromycosis in HIV/AIDS patients: a retrospective study[J].Mycopath-ologia,2021,186(2):269-276.[17]刘敏,石峰,吴玉珊,等.以依非韦伦为基础的抗病毒治疗方案对成人人类免疫缺陷病毒感染者血脂影响的临床研究[J].中国感染与化疗杂志,2019,19(4):366-370.[18]丁莉莎,贺健梅,覃碧云,等.合并HBV或/和HCV感染的HIV-1患者抗病毒治疗效果[J].中国病毒病杂志,2018,8(3):189-193.[19]覃善芳,江建宁,黄维,等.替诺福韦对初治人类免疫缺陷病毒感染者和艾滋病患者肾功能的影响[J].中华传染病杂志,2018,36(2):78-82.[20]刘胜昔.替诺福韦与拉米夫定联合治疗艾滋病合并乙型肝炎病毒72周疗效观察[J].现代中西医结合杂志,2017,26(9):992-994.

相似文献/References:

[1]陈新华.拉米夫定联合恩替卡韦治疗乙型肝炎相关肝硬化的 长期疗效与安全性分析[J].医学信息,2019,32(18):151.[doi:10.3969/j.issn.1006-1959.2019.18.052]
　CHEN Xin-hua.Long-term Efficacy and Safety of Lamivudine Combined with Entecavir in the Treatment of Hepatitis B-related Cirrhosis[J].Journal of Medical Information,2019,32(15):151.[doi:10.3969/j.issn.1006-1959.2019.18.052]
[2]张 娜.不同种类核苷类似物治疗慢性乙型肝炎患者的疗效及对HBsAg水平的影响[J].医学信息,2021,34(09):96.[doi:10.3969/j.issn.1006-1959.2021.09.025]
　ZHANG Na.Efficacy of Different Kinds of Nucleoside Analogues in the Treatment of Patients with Chronic Hepatitis B and Their Influence on HBsAg Levels[J].Journal of Medical Information,2021,34(15):96.[doi:10.3969/j.issn.1006-1959.2021.09.025]

更新日期/Last Update: 1900-01-01